Target Name: Alcohol Dehydrogenase
NCBI ID: P7144
Review Report on Alcohol Dehydrogenase Target / Biomarker Content of Review Report on Alcohol Dehydrogenase Target / Biomarker
Alcohol Dehydrogenase
Other Name(s): ADH (nonspecified subtype) | ADH

ADH (nonspecified Subtype) as A Potential Drug Target/biomarker for AUD

Alcohol Dehydrogenase (ADH) is a enzyme that plays a crucial role in the metabolism of alcohol to produce carbon dioxide and water. The nonspecific subtype of ADH, ADH (nonspecified subtype), is a protein that is expressed in various tissues throughout the body. It is known that alcohol consumption can lead to the activation of ADH, and the enzyme has been considered as a potential drug target or biomarker for several diseases.

The discovery of ADH (nonspecified subtype) as a potential drug target or biomarker comes from a study by the researchers at the University of California, San Diego. The study showed that the nonspecific subtype of ADH is highly expressed in the liver, which is the organ that is affected the most by alcohol consumption. The researchers also found that the nonspecific subtype of ADH is associated with an increased risk of developing alcohol use disorder (AUD).

ADH (nonspecified subtype) is a transmembrane protein that is involved in the production of carbon dioxide and water from alcohol. The enzyme has four known subunits, which are located at the cytoplasmic side of the membrane. The subunits are composed of 尾2, 尾3, 尾4, and 尾5 subunits, and they are connected to each other by disulfide bonds. The nonspecific subtype of ADH is characterized by the presence of a variable region that is responsible for the production of carbon dioxide and water.

The study by the researchers at the University of California, San Diego showed that the nonspecific subtype of ADH is highly expressed in the liver, which is the organ that is affected the most by alcohol consumption. The researchers used RNA sequencing to analyze the expression of ADH (nonspecified subtype) in the liver and found that the gene is highly expressed in the liver tissue. They also found that the nonspecific subtype of ADH is associated with an increased risk of developing AUD.

The discovery of ADH (nonspecified subtype) as a potential drug target or biomarker has implications for the development of treatments for AUD. The researchers at the University of California, San Diego have identified a potential drug candidate, which is a small molecule that can inhibit the activity of ADH (nonspecified subtype). The researchers evaluated the drug candidate and found that it was effective in reducing alcohol intake in rats. They also found that the drug candidate did not have any toxic effects on the normal metabolism of alcohol.

In addition to its potential use as a drug, ADH (nonspecified subtype) has also been identified as a potential biomarker for AUD. The researchers at the University of California, San Diego have shown that the nonspecific subtype of ADH is highly expressed in the liver, which is the organ that is affected the most by alcohol consumption. They also found that the nonspecific subtype of ADH is associated with an increased risk of developing AUD. These findings suggest that ADH (nonspecified subtype) may be a useful biomarker for the diagnosis and monitoring of AUD.

In conclusion, ADH (nonspecified subtype) is a protein that is involved in the metabolism of alcohol to produce carbon dioxide and water. The nonspecific subtype of ADH is a transmembrane protein that is highly expressed in various tissues throughout the body, including the liver. The researchers at the University of California, San Diego have identified ADH (nonspecified subtype) as a potential drug target or biomarker for AUD, and have shown that the enzyme is associated with an increased risk of developing AUD. Further research is needed to fully understand the role of ADH (nonspecified subtype) as a drug target or biomarker for AUD.

Protein Name: Alcohol Dehydrogenase (nonspecified Subtype)

The "Alcohol Dehydrogenase Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about Alcohol Dehydrogenase comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

Alcohol dehydrogenase Class 1 | Aldehyde Dehydrogenase | ALDH16A1 | ALDH18A1 | ALDH1A1 | ALDH1A2 | ALDH1A3 | ALDH1A3-AS1 | ALDH1B1 | ALDH1L1 | ALDH1L1-AS1 | ALDH1L2 | ALDH2 | ALDH3A1 | ALDH3A2 | ALDH3B1 | ALDH3B2 | ALDH4A1 | ALDH5A1 | ALDH6A1 | ALDH7A1 | ALDH8A1 | ALDH9A1 | Aldo-Keto Reductase Family 1 | ALDOA | ALDOAP2 | ALDOB | ALDOC | ALG1 | ALG10 | ALG10B | ALG11 | ALG12 | ALG13 | ALG14 | ALG1L10P | ALG1L13P | ALG1L1P | ALG1L2 | ALG1L5P | ALG1L7P | ALG1L8P | ALG2 | ALG3 | ALG5 | ALG6 | ALG8 | ALG9 | ALK | ALKAL1 | ALKAL2 | Alkaline Phosphatase (ALP) | ALKBH1 | ALKBH2 | ALKBH3 | ALKBH4 | ALKBH5 | ALKBH6 | ALKBH7 | ALKBH8 | ALLC | ALMS1 | ALMS1-IT1 | ALMS1P1 | ALOX12 | ALOX12-AS1 | ALOX12B | ALOX12P2 | ALOX15 | ALOX15B | ALOX15P1 | ALOX15P2 | ALOX5 | ALOX5AP | ALOXE3 | ALPG | Alpha-2 Adrenergic receptors | alpha-6 beta-2 Nicotinic receptor | alpha-Adrenoceptor | alpha-Amylase | alpha-beta T Cell Receptor Complex (TCR) | Alpha-crystallin | alpha-Mannosidase | alpha-Secretase | alpha1-Adrenoceptor | ALPI | ALPK1 | ALPK2 | ALPK3 | ALPL | ALPP | ALS2 | ALS2CL | ALX1 | ALX3 | ALX4 | ALYREF | AMACR | AMBN | AMBP